Patents by Inventor Jason D. Brubaker
Jason D. Brubaker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9884830Abstract: The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines and tetracycline analogs described provides an efficient and enantioselective route to a variety of tetracycline analogs and polycyclines previously inaccessible via earlier tetracycline syntheses and semi-synthetic methods. These analogs may be used as anti-microbial agents or anti-proliferative agents in the treatment of diseases of humans or other animals.Type: GrantFiled: May 20, 2016Date of Patent: February 6, 2018Assignee: President and Fellows of Harvard CollegeInventors: Andrew G. Myers, Mark G. Charest, Christian D. Lerner, Jason D. Brubaker, Dionicio R. Siegel
-
Publication number: 20180030032Abstract: Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.Type: ApplicationFiled: July 26, 2017Publication date: February 1, 2018Inventors: Jason D. BRUBAKER, LUCIAN V. DIPIETRO
-
Publication number: 20180022732Abstract: Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.Type: ApplicationFiled: July 21, 2017Publication date: January 25, 2018Inventors: JASON D. BRUBAKER, TIMOTHY GUZI, KEVIN J. WILSON, LUCIAN V. DIPIETRO, YULIAN ZHANG, DOUGLAS WILSON, PAUL E. FLEMING
-
Publication number: 20170298069Abstract: Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.Type: ApplicationFiled: April 14, 2017Publication date: October 19, 2017Inventors: Natasja Brooijmans, Jason D. Brubaker, Mark Cronin, Paul E. Fleming, Brian L. Hodous, Joseph L. Kim, Josh Waetzig, Brett Williams, Douglas Wilson, Kevin J. Wilson
-
Publication number: 20170275297Abstract: The present invention relates to inhibitors of IRAK4 of Formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.Type: ApplicationFiled: September 25, 2015Publication date: September 28, 2017Applicant: MERCK SHARP & DOHME CORP.Inventors: Michael D. ALTMAN, Brian M. ANDRESEN, Jason D. BRUBAKER, Matthew L. CHILDERS, Anthony DONOFRIO, Thierry FISCHMANN, Craig R. GIBEAU, Solomon D. KATTAR, Charles A. LESBURG, Jongwon LIM, John K.F. MACLEAN, Umar F. MANSOOR, Alan B. NORTHRUP, John SANDERS, Graham F. SMITH, Luis TORRES
-
Publication number: 20170267661Abstract: Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.Type: ApplicationFiled: March 17, 2017Publication date: September 21, 2017Inventors: Joseph L. Kim, Douglas J. Kevin, Jason D. Brubaker
-
Publication number: 20170247388Abstract: The present invention relates to inhibitors of IRAK4 of Formula I and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.Type: ApplicationFiled: September 25, 2015Publication date: August 31, 2017Applicant: MERCK SHARP & DOHME CORP.Inventors: MICHAEL D. ALTMAN, JASON D. BRUBAKER, MATTHEW L. CHILDERS, ANTHONY DONOFRIO, THIERRY FISCHMANN, CRAIG R. GIBEAU, SOLOMON D. KATTAR, CHARLES A. LESBURG, JONGWON LIM, JOHN K.F. MACLEAN, UMAR F. MANSOOR, ALAN B. NORTHRUP, JOHN M. SANDERS, GRAHAM F. SMITH
-
Publication number: 20170217981Abstract: The present invention relates to inhibitors of IRAK4 of Formula I and provides compositions comprising such inhibutors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.Type: ApplicationFiled: September 25, 2015Publication date: August 3, 2017Applicant: MERCK SHARP & DOHME CORP.Inventors: MICHAEL D. ALTMAN, JASON D. BRUBAKER, MATTHEW L. CHILDERS, ANTHONY DONOFRIO, THIERRY FISCHMANN, CRAIG R. GIBEAU, SOLOMON D. KATTAR, CHARLES A. LESBURG, JONGWON LIM, JOHN K.F. MACLEAN, UMAR F. MANSOOR, ALAN B. NORTHRUP, JOHN M. SANDERS, GRAHAM F. SMITH
-
Publication number: 20170209446Abstract: The present invention relates to inhibitors of IRAK4 of Formula I and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.Type: ApplicationFiled: September 25, 2015Publication date: July 27, 2017Applicant: MERCK SHARP & DOHME CORP.Inventors: MICHAEL D. ALTMAN, BRIAN M. ANDRESEN, JASON D. BRUBAKER, ANTHONY DONOFRIO, THIERRY FISCHMANN, CRAIG R. GIBEAU, CHARLES A. LESBURG, JONGWON LIM, JOHN K.F. MACLEAN, UMAR F. MANSOOR, ALAN B. NORTHRUP, JOHN M. SANDERS, GRAHAM F. SMITH, LUIS TORRES
-
Publication number: 20170121312Abstract: Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.Type: ApplicationFiled: November 1, 2016Publication date: May 4, 2017Inventors: Jason D. Brubaker, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Lucian V. DiPietro
-
Publication number: 20160340325Abstract: The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines and tetracycline analogs described provides an efficient and enantioselective route to a variety of tetracycline analogs and polycyclines previously inaccessible via earlier tetracycline syntheses and semi-synthetic methods. These analogs may be used as anti-microbial agents or anti-proliferative agents in the treatment of diseases of humans or other animals.Type: ApplicationFiled: May 20, 2016Publication date: November 24, 2016Applicant: President and Fellows of Harvard CollegeInventors: Andrew G. Myers, Mark G. Charest, Christian D. Lerner, Jason D. Brubaker, Dionicio R. Siegel
-
Patent number: 9365493Abstract: The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines and tetracycline analogs described provides an efficient and enantioselective route to a variety of tetracycline analogs and polycyclines previously inaccessible via earlier tetracycline syntheses and semi-synthetic methods. These analogs may be used as anti-microbial agents or anti-proliferative agents in the treatment of diseases of humans or other animals.Type: GrantFiled: October 25, 2013Date of Patent: June 14, 2016Assignee: President and Fellows of Harvard CollegeInventors: Andrew G. Myers, Mark G. Charest, Christian D. Lerner, Jason D. Brubaker, Dionicio R. Siegel
-
Patent number: 8937077Abstract: The instant invention provides compounds of formula I which are Jak inhibitors, and as such are useful for the treatment of Jak-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.Type: GrantFiled: October 17, 2011Date of Patent: January 20, 2015Assignee: Merck Sharp & Dohme Corp.Inventors: David Joseph Guerin, Jason D. Brubaker, Michelle Martinez, Joon O. Jung, Neville J. Anthony, Mark E. Scott, Carolyn Michele Cammarano, Dawn Marie Mampreian Hoffman, Hyun Chong Woo, Christopher J. Dinsmore, Philip Jones
-
Patent number: 8907104Abstract: The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The recent development of a modular synthesis of tetracycline analogs through a chiral enone intermediate has allowed for the efficient synthesis of novel tetracycline analogs never prepared before. The present invention provides a more efficient route for preparing the enone intermediate.Type: GrantFiled: November 11, 2013Date of Patent: December 9, 2014Assignee: President and Fellows of Harvard CollegeInventors: Andrew G. Myers, Jason D. Brubaker
-
Publication number: 20140179929Abstract: The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The recent development of a modular synthesis of tetracycline analogs through a chiral enone intermediate has allowed for the efficient synthesis of novel tetracycline analogs never prepared before. The present invention provides a more efficient route for preparing the enone intermediate.Type: ApplicationFiled: November 11, 2013Publication date: June 26, 2014Applicant: President and Fellows of Harvard CollegeInventors: Andrew G. Myers, Jason D. Brubaker
-
Publication number: 20140163238Abstract: The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines and tetracycline analogs described provides an efficient and enantioselective route to a variety of tetracycline analogs and polycyclines previously inaccessible via earlier tetracycline syntheses and semi-synthetic methods. These analogs may be used as anti-microbial agents or anti-proliferative agents in the treatment of diseases of humans or other animals.Type: ApplicationFiled: October 25, 2013Publication date: June 12, 2014Applicant: President and Fellows of Harvard CollegeInventors: Andrew G. Myers, Mark G. Charest, Christian D. Lerner, Jason D. Brubaker, Dionicio R. Siegel
-
Patent number: 8598148Abstract: The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines and tetracycline analogs described provides an efficient and enantioselective route to a variety of tetracycline analogs and polycyclines previously inaccessible via earlier tetracycline syntheses and semi-synthetic methods. These analogs may be used as anti-microbial agents or anti-proliferative agents in the treatment of diseases of humans or other animals.Type: GrantFiled: May 12, 2010Date of Patent: December 3, 2013Assignee: President and Fellows of Harvard CollegeInventors: Andrew G. Myers, Mark G. Charest, Christian D. Lerner, Jason D. Brubaker, Dionicio R. Siegel
-
Patent number: 8580969Abstract: The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The recent development of a modular synthesis of tetracycline analogs through a chiral enone intermediate has allowed for the efficient synthesis of novel tetracycline analogs never prepared before. The present invention provides a more efficient route for preparing the enone intermediate.Type: GrantFiled: September 14, 2012Date of Patent: November 12, 2013Assignee: President and Fellows of Harvard CollegeInventors: Andrew G. Myers, Jason D. Brubaker
-
Publication number: 20130225577Abstract: The instant invention provides compounds of formula I which are Jak inhibitors, and as such are useful for the treatment of Jak-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.Type: ApplicationFiled: October 17, 2011Publication date: August 29, 2013Inventors: David Joseph Guerin, Jason D. Brubaker, Michelle Martinez, Joon O. Jung, Neville J. Anthony, Mark E. Scott, Carolyn Michele Cammarano, Dawn Marie Mampreian Hoffman, Hyun Chong Woo, Christopher J. Dinsmore, Philip Jones
-
Publication number: 20130217886Abstract: The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The recent development of a modular synthesis of tetracycline analogs through a chiral enone intermediate has allowed for the efficient synthesis of novel tetracycline analogs never prepared before. The present invention provides a more efficient route for preparing the enone intermediate.Type: ApplicationFiled: September 14, 2012Publication date: August 22, 2013Applicant: President and Fellows of Harvard CollegeInventors: Andrew G. Myers, Jason D. Brubaker